Shareholding disclosure

Rudolf Maag

Declared position

4.06%

Threshold

Crossed upwards

Timeline

Published

15.08.2013

Transaction

08.08.2013

Voting rights breakdown

Voting rights acquired4.06%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAD8D000B5

Beneficial owner

Rudolf Maag

Declared address

Rudolf MAAG, 4102 Binningen

Erwerb von Aktien aus Kapitalerhöhung Die Firma ist zu 100% beherrscht von Rudolf Maag

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Rudolf Maag

Addex Therapeutics Ltd15.08.2013TAD8D000B5

Disclosure summary

Rudolf Maag disclosed a holding in Addex Therapeutics Ltd on the acquisition side, published by SIX Exchange Regulation on 15.08.2013, at 4.06% of voting rights. Notice category: Single shareholder.

Disclosed position

4.06%

Voting rights acquired

Voting rights acquired4.06%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Rudolf Maag disclosed a holding in Addex Therapeutics Ltd, published on 15.08.2013.

Publication date15.08.2013

Transaction date08.08.2013

Issuing companyAddex Therapeutics Ltd

Beneficial ownerRudolf Maag

Declared addressRudolf MAAG, 4102 Binningen

CategorySingle shareholder

Voting rights acquired4.06%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAD8D000B5

Conditions

Erwerb von Aktien aus Kapitalerhöhung Die Firma ist zu 100% beherrscht von Rudolf Maag

Source: SIX Exchange Regulation · Publication date: 15.08.2013

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open